

FILE 'CA' ENTERED AT 15:46:08 ON 14 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2006 VOL 145 ISS 12
FILE LAST UPDATED: 7 Sep 2006 (20060907/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s amphotericin and pure
 7022 AMPHOTERICIN
 422650 PURE
L1 68 AMPHOTERICIN AND PURE

=> s l1 and chromatography
 310553 CHROMATOGRAPHY
L2 1 L1 AND CHROMATOGRAPHY

=> d l2 1 an ab

L2 ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN
AN 135:142230 CA

AB The invention discloses highly purified daptomycin and to pharmaceutical comps. comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatog., hydrophobic interaction chromatog. and anion exchange chromatog. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatog. An improved method for producing daptomycin by fermentation of *Streptomyces roseosporus* is described. The invention also discloses HPLC methods for anal. of daptomycin purity. Methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin, and using them therapeutically are disclosed. Thus, daptomycin was produced in a fermentation culture of *S. roseosporus* and partially purified daptomycin (9.9 Kg) was purified by microfiltration from 5500 L of fermentation broth. The partially purified daptomycin was further purified and resulted in a bulk daptomycin preparation with a purity of 91%. The daptomycin preparation contained 14 impurities as determined by HPLC anal. The daptomycin preparation was applied to a

Poros P150 anion exchange resin (PE Biosystems) in Tris buffer pH 7.0 containing 6M urea and allowed to bind to the resin. The resin was washed with 3 column vols. of buffer prior to initiation of a NaCl gradient in the same buffer. Alternatively, the contaminants can be effectively removed from the column with a fixed salt level of 30 mM NaCl. The elution of purified daptomycin from the resin occurred at approx. 300 mM NaCl during a 0 to 1000 mM NaCl gradient. Daptomycin eluted from the column was greater than 99% pure as measured by the "first" HPLC

method. The purified daptomycin contained only one detectable daptomycin contaminant. Anhydrodaptomycin and B-isomer were undetectable (<0.01% contamination). The level of the unidentified contaminant was 0.1-0.5%.

=> d his

(FILE 'HOME' ENTERED AT 15:45:30 ON 14 SEP 2006)

FILE 'CA' ENTERED AT 15:46:08 ON 14 SEP 2006

L1 68 S AMPHOTERICIN AND PURE
L2 1 S L1 AND CHROMATOGRAPHY